CA2148898A1 - Proteine p54 activee par le stress - Google Patents

Proteine p54 activee par le stress

Info

Publication number
CA2148898A1
CA2148898A1 CA 2148898 CA2148898A CA2148898A1 CA 2148898 A1 CA2148898 A1 CA 2148898A1 CA 2148898 CA2148898 CA 2148898 CA 2148898 A CA2148898 A CA 2148898A CA 2148898 A1 CA2148898 A1 CA 2148898A1
Authority
CA
Canada
Prior art keywords
polypeptide
seq
leu
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2148898
Other languages
English (en)
Inventor
John M. Kyriakis
Joseph Avruch
Papia Banerjee
James R. Woodgett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ontario Cancer Institute
General Hospital Corp
Original Assignee
John M. Kyriakis
Joseph Avruch
Papia Banerjee
James R. Woodgett
The General Hospital Corporation
Ontario Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John M. Kyriakis, Joseph Avruch, Papia Banerjee, James R. Woodgett, The General Hospital Corporation, Ontario Cancer Institute filed Critical John M. Kyriakis
Publication of CA2148898A1 publication Critical patent/CA2148898A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2148898 1994-05-09 1995-05-08 Proteine p54 activee par le stress Abandoned CA2148898A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24001494A 1994-05-09 1994-05-09
US08/240,014 1994-05-09

Publications (1)

Publication Number Publication Date
CA2148898A1 true CA2148898A1 (fr) 1995-11-10

Family

ID=22904740

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2148898 Abandoned CA2148898A1 (fr) 1994-05-09 1995-05-08 Proteine p54 activee par le stress

Country Status (1)

Country Link
CA (1) CA2148898A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788531A1 (fr) * 1999-01-20 2000-07-21 Aventis Pharma Sa Nouveaux polypeptides derives de la proteine jnk3 humaine, leurs variants, les sequences nucleotidiques correspondantes, et leurs utilisations
WO2000043524A1 (fr) * 1999-01-20 2000-07-27 Aventis Pharma S.A. Polypeptides derives de jnk3
WO2002012338A2 (fr) * 2000-08-03 2002-02-14 Grünenthal GmbH Procede de criblage
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US7264942B2 (en) 1998-05-14 2007-09-04 Ya Fang Liu Method for identifying JNK and MLK inhibitors for treatment of neurological conditions
US7452686B2 (en) 1998-05-14 2008-11-18 Ya Fang Liu JNK inhibitors for the treatment of neurological disorders
FR2788531A1 (fr) * 1999-01-20 2000-07-21 Aventis Pharma Sa Nouveaux polypeptides derives de la proteine jnk3 humaine, leurs variants, les sequences nucleotidiques correspondantes, et leurs utilisations
WO2000043524A1 (fr) * 1999-01-20 2000-07-27 Aventis Pharma S.A. Polypeptides derives de jnk3
US6649388B2 (en) 1999-01-20 2003-11-18 Aventis Pharma S.A. Polypeptides derived from JNK3
WO2002012338A2 (fr) * 2000-08-03 2002-02-14 Grünenthal GmbH Procede de criblage
WO2002012338A3 (fr) * 2000-08-03 2002-12-19 Gruenenthal Gmbh Procede de criblage
EP1469316A1 (fr) * 2000-08-03 2004-10-20 Grünenthal GmbH Procédé de criblage

Similar Documents

Publication Publication Date Title
Kyriakis et al. The stress-activated protein kinase subfamily of c-Jun kinases
Rahman et al. Gαq and Gβγ regulate PAR-1 signaling of thrombin-induced NF-κB activation and ICAM-1 transcription in endothelial cells
Laine et al. The protooncogene TCL1 is an Akt kinase coactivator
Liu et al. Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor.
Inagaki et al. Cardioprotection by ε-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an ε-protein kinase C-activating peptide
Kirken et al. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells
US8658594B2 (en) Peptide inhibitors of protein kinase C
Bian et al. Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins
Kaufmann et al. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor-and cAMP-mediated signaling
Tharaux et al. Rho kinase promotes alloimmune responses by regulating the proliferation and structure of T cells
Øie et al. Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats
CA2126523A1 (fr) Kinases jak et regulation de la transduction du signal des cytokines
Ohbayashi et al. LIF-and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation
AU752617B2 (en) A novel human checkpoint kinase, hCDS1, compositions and methods
US7741290B2 (en) Method of preventing progression of hypertension-induced heart failure with PKC peptides
US5621075A (en) Insulin receptor substrate
CZ298866B6 (cs) Izolovaný polypeptid, izolovaná sekvence DNA, farmaceutická kompozice a použití izolovaného polypeptidu pro výrobu farmaceutického prostredku
Kessler et al. Diversification of cardiac insulin signaling involves the p85α/β subunits of phosphatidylinositol 3-kinase
US6326181B1 (en) Cell volume-regulated human kinase h-sgk
Bryson et al. The deleterious role of the prostaglandin E2 EP3 receptor in angiotensin II hypertension
CA2411396A1 (fr) Inhibiteurs de la hmg coa reductase pour favoriser l'angiogenese
US7368113B2 (en) Hormonally up-regulated, neu-tumor-associated kinase
JP2002528390A (ja) 細胞の生存を増強するためのakt組成物
US5830699A (en) SOK-1 and methods of use
Flores-Morales et al. In vitro interaction between STAT 5 and JAK 2; dependence upon phosphorylation status of STAT 5 and JAK 2

Legal Events

Date Code Title Description
FZDE Dead